Randall Ow
Otolaryngology · Roseville, CANPI 1336142009
Payments from drug & device makers
Across 1,579 payments — averaging $2708.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$860K
- Aerin Medical Inc.$575K
- GSK$470K
- Livanova USA, Inc.$453K
- Sanofi US Services Inc.$423K
- Biohaven Pharmaceutical Holding Company Ltd.$297K
- plus $1.2M from 29 others
Across 38 payments — averaging $19,675 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurent Medical Limited$462K
- Hill Dermaceuticals, Inc.$277K
- F. Hoffmann-la Roche AG$7K
- Insmed, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 226 | $859,555 |
| Aerin Medical Inc. | 94 | $575,049 |
| GSK | 154 | $470,394 |
| Livanova USA, Inc. | 92 | $452,802 |
| Sanofi US Services Inc. | 29 | $423,029 |
| Biohaven Pharmaceutical Holding Company Ltd. | 290 | $296,868 |
| AstraZeneca | 18 | $234,237 |
| Regeneron Healthcare Solutions, Inc. | 260 | $215,993 |
| Roche Products Limited | 22 | $195,186 |
| Stryker | 122 | $153,494 |
| Intersect ENT, Inc. | 40 | $74,801 |
| Smith+Nephew | 31 | $62,873 |
| Sanofi | 53 | $46,966 |
| Eli Lilly | 2 | $45,731 |
| Hill Dermaceuticals, Inc. | 1 | $42,577 |
| Insmed, Inc. | 22 | $37,082 |
| Genentech, Inc. | 10 | $25,051 |
| Regeneron | 3 | $13,365 |
| Medtronic(2 entities) | 13 | $12,590 |
| Genentech USA, Inc. | 7 | $10,012 |
| Arrinex, Inc. | 3 | $9,119 |
| F. Hoffmann-la Roche AG | 11 | $5,644 |
| Paratek Pharmaceuticals, Inc. | 6 | $5,445 |
| Novartis | 2 | $3,893 |
| Inspire Medical Systems, Inc. | 49 | $3,216 |
| Cochlear Americas | 2 | $310 |
| KARL Storz Endoscopy-america | 3 | $256 |
| Lilly USA, LLC | 2 | $114 |
| Johnson & Johnson(2 entities) | 2 | $109 |
| Alk-abello, Inc | 3 | $107 |
| ZOLL Respicardia, Inc. | 2 | $100 |
| Neurent Medical Limited | 2 | $90 |
| Acclarent, Inc | 1 | $26 |
| Amgen | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
How this compares
$4,276,112 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other otolaryngology in Roseville
- Timothy FifeRoseville$64K
- Robert FinnRoseville$62K
- Amir MoradiVista$2.6M
- Brian WeeksSan Diego$1.6M
- Charles LimbSan Francisco$1.5M
- Andrew BerosSan Diego$688K
- Paul SchalchChula Vista$573K
- Steven DavisTorrance$544K
- Arnaud BewleySacramento$541K
- Keith BlackwellLos Angeles$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.